The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. Court of Appeals for the 4th Circuit, urging the court to affirm a decision by the U.S. District Court for the District of Maryland in September to deny a preliminary injunction sought by drug companies and PhRMA against enforcement of Maryland's state law protecting 340B pricing for contract pharmacy arrangements.  

The AHA also filed amicus briefs in the district court in July and August, defending Maryland’s law against drug industry efforts to enjoin it.  

Others joining AHA in the Feb. 28 filing were 340B Health, the Maryland Hospital Association, the Mid-Atlantic Association of Community Health Centers and the American Society of Health-System Pharmacists. 

Related News Articles

Headline
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…
Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…